Beyond Biotech - the podcast from Labiotech

The ADC patent cliff: a turning point for rare cancer treatment

• Labiotech • Episode 224

Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.

0:00 | 36:09

Antibody-drug conjugates are one of the hottest areas in oncology. They pair the precision of an antibody with a potent drug payload, and the data keeps getting stronger. ESMO 2026 brought another wave of promising readouts. But could ADCs do more than add new options for common cancers? Could they let doctors target the molecular makeup of each patient’s tumour, whatever type of cancer it is?

That’s the promise. The reality is more complicated. High development costs, crowded patent landscapes and limited tumour profiling all push developers towards the largest patient groups. That leaves people with rarer cancers behind.

My guest today is Robert Andrews, Partner and Patent Attorney at Mewburn Ellis. Robert has spent more than 20 years advising ADC companies on patent strategy. We talk about where the field is heading, what patent expiries could unlock, and what needs to change for ADCs to deliver truly personalised cancer care.

01:28 Meet Robert Andrews

06:18 How ADCs could shift cancer treatment towards molecular profiling

09:45 ADC highlights from ESMO 2026 and China’s rise

15:00 Development costs, rare cancers and layered ADC patents

24:04 Patent expiries, biosimilar ADCs and the UPC

31:24 The next decade of ADCs and lessons from Korea

Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! 

Stay updated by subscribing to our newsletter

To dive deeper into the topic: